tiprankstipranks
Trending News
More News >
Prothena (PRTA)
NASDAQ:PRTA
US Market

Prothena (PRTA) Stock Forecast & Price Target

Compare
641 Followers
See the Price Targets and Ratings of:

PRTA Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
4 Buy
4 Hold
1 Sell
Based on 9 analysts giving stock ratings to
Prothena
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRTA Stock 12 Month Forecast

Average Price Target

$24.29
▲(299.51%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $24.29 with a high forecast of $81.00 and a low forecast of $4.00. The average price target represents a 299.51% change from the last price of $6.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","82":"$82","22.75":"$22.8","42.5":"$42.5","62.25":"$62.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$81.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,22.75,42.5,62.25,82],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,10.532307692307693,16.404615384615383,22.276923076923076,28.14923076923077,34.02153846153846,39.893846153846155,45.76615384615384,51.63846153846154,57.51076923076923,63.38307692307693,69.25538461538461,75.1276923076923,{"y":81,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,6.17,7.68,9.190000000000001,10.7,12.21,13.72,15.23,16.740000000000002,18.25,19.759999999999998,21.27,22.78,{"y":24.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,4.609230769230769,4.558461538461539,4.507692307692308,4.456923076923077,4.406153846153846,4.355384615384615,4.304615384615385,4.253846153846154,4.203076923076923,4.1523076923076925,4.101538461538461,4.050769230769231,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.37,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.53,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.27,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$81.00Average Price Target$24.29Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PRTA
TipRanks AITipRanks
Not Ranked
TipRanks
$5.5
Hold
-9.54%
Downside
Reiterated
06/19/25
Prothena's overall stock score is primarily affected by its weak financial performance and bearish technical indicators. While the advancement of prasinezumab offers a potential growth opportunity, significant challenges remain due to negative profitability and cash flow metrics. The lack of earnings call data limits insights into management's future strategies.
Cantor Fitzgerald Analyst forecast on PRTA
Eric Schmidt FCACantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterated
06/20/25
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)
Oppenheimer Analyst forecast on PRTA
Jay OlsonOppenheimer
Oppenheimer
Hold
Reiterated
06/16/25
Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)
Bank of America Securities Analyst forecast on PRTA
Tazeen AhmadBank of America Securities
Bank of America Securities
$22$4
Sell
-34.21%
Downside
Downgraded
05/28/25
Prothena downgraded to Underperform from Neutral at BofAProthena downgraded to Underperform from Neutral at BofA
H.C. Wainwright Analyst forecast on PRTA
Andrew FeinH.C. Wainwright
H.C. Wainwright
$30$14
Buy
130.26%
Upside
Reiterated
05/27/25
Prothena's Strategic Shift and Promising Alzheimer's Pipeline Drive Buy Rating
Piper Sandler Analyst forecast on PRTA
Yasmeen RahimiPiper Sandler
Piper Sandler
$110$81
Buy
1232.24%
Upside
Reiterated
05/27/25
Prothena price target lowered to $81 from $110 at Piper SandlerProthena price target lowered to $81 from $110 at Piper Sandler
Citizens JMP Analyst forecast on PRTA
Jason ButlerCitizens JMP
Citizens JMP
$78$29
Buy
376.97%
Upside
Reiterated
05/27/25
Prothena (PRTA) Receives a Buy from Citizens JMP
Jefferies Analyst forecast on PRTA
Michael YeeJefferies
Jefferies
$32$6
Hold
-1.32%
Downside
Downgraded
05/27/25
Prothena's Hold Rating: Clinical Trial Challenges and Financial PressuresJefferies analyst Michael Yee downgraded Prothena Corp (NASDAQ: PRTA) from Buy to Hold with a price target of $6.00 (from $32.00).
Chardan Capital Analyst forecast on PRTA
Rudy LiChardan Capital
Chardan Capital
$40$18
Buy
196.05%
Upside
Reiterated
05/26/25
Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Bristol-Myers Squibb (NYSE: BMY)
RBC Capital Analyst forecast on PRTA
Brian AbrahamsRBC Capital
RBC Capital
$20$18
Hold
196.05%
Upside
Reiterated
05/08/25
RBC Capital Remains a Hold on Prothena (PRTA)
Evercore ISI Analyst forecast on PRTA
Umer RaffatEvercore ISI
Evercore ISI
Buy
Reiterated
02/21/25
Analysts Are Bullish on Top Healthcare Stocks: Prothena (PRTA), Dexcom (DXCM)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PRTA
TipRanks AITipRanks
Not Ranked
TipRanks
$5.5
Hold
-9.54%
Downside
Reiterated
06/19/25
Prothena's overall stock score is primarily affected by its weak financial performance and bearish technical indicators. While the advancement of prasinezumab offers a potential growth opportunity, significant challenges remain due to negative profitability and cash flow metrics. The lack of earnings call data limits insights into management's future strategies.
Cantor Fitzgerald Analyst forecast on PRTA
Eric Schmidt FCACantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterated
06/20/25
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)
Oppenheimer Analyst forecast on PRTA
Jay OlsonOppenheimer
Oppenheimer
Hold
Reiterated
06/16/25
Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)
Bank of America Securities Analyst forecast on PRTA
Tazeen AhmadBank of America Securities
Bank of America Securities
$22$4
Sell
-34.21%
Downside
Downgraded
05/28/25
Prothena downgraded to Underperform from Neutral at BofAProthena downgraded to Underperform from Neutral at BofA
H.C. Wainwright Analyst forecast on PRTA
Andrew FeinH.C. Wainwright
H.C. Wainwright
$30$14
Buy
130.26%
Upside
Reiterated
05/27/25
Prothena's Strategic Shift and Promising Alzheimer's Pipeline Drive Buy Rating
Piper Sandler Analyst forecast on PRTA
Yasmeen RahimiPiper Sandler
Piper Sandler
$110$81
Buy
1232.24%
Upside
Reiterated
05/27/25
Prothena price target lowered to $81 from $110 at Piper SandlerProthena price target lowered to $81 from $110 at Piper Sandler
Citizens JMP Analyst forecast on PRTA
Jason ButlerCitizens JMP
Citizens JMP
$78$29
Buy
376.97%
Upside
Reiterated
05/27/25
Prothena (PRTA) Receives a Buy from Citizens JMP
Jefferies Analyst forecast on PRTA
Michael YeeJefferies
Jefferies
$32$6
Hold
-1.32%
Downside
Downgraded
05/27/25
Prothena's Hold Rating: Clinical Trial Challenges and Financial PressuresJefferies analyst Michael Yee downgraded Prothena Corp (NASDAQ: PRTA) from Buy to Hold with a price target of $6.00 (from $32.00).
Chardan Capital Analyst forecast on PRTA
Rudy LiChardan Capital
Chardan Capital
$40$18
Buy
196.05%
Upside
Reiterated
05/26/25
Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Bristol-Myers Squibb (NYSE: BMY)
RBC Capital Analyst forecast on PRTA
Brian AbrahamsRBC Capital
RBC Capital
$20$18
Hold
196.05%
Upside
Reiterated
05/08/25
RBC Capital Remains a Hold on Prothena (PRTA)
Evercore ISI Analyst forecast on PRTA
Umer RaffatEvercore ISI
Evercore ISI
Buy
Reiterated
02/21/25
Analysts Are Bullish on Top Healthcare Stocks: Prothena (PRTA), Dexcom (DXCM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Prothena

1 Month
xxx
Success Rate
5/20 ratings generated profit
25%
Average Return
-4.94%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 25.00% of your transactions generating a profit, with an average return of -4.94% per trade.
3 Months
xxx
Success Rate
5/20 ratings generated profit
25%
Average Return
-9.86%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -9.86% per trade.
1 Year
Jason ButlerCitizens JMP
Success Rate
2/20 ratings generated profit
10%
Average Return
-36.20%
reiterated a buy rating last month
Copying Jason Butler's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -36.20% per trade.
2 Years
xxx
Success Rate
0/20 ratings generated profit
0%
Average Return
-67.83%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -67.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRTA Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
May 25
Jun 25
Strong Buy
13
11
12
14
13
Buy
0
0
1
1
1
Hold
2
2
3
6
8
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
15
13
16
22
23
In the current month, PRTA has received 14 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. PRTA average Analyst price target in the past 3 months is 24.29.
Each month's total comprises the sum of three months' worth of ratings.

PRTA Financial Forecast

PRTA Earnings Forecast

Next quarter’s earnings estimate for PRTA is -$1.22 with a range of -$2.07 to -$0.50. The previous quarter’s EPS was -$1.12. PRTA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.18% of the time in the same period. In the last calendar year PRTA has Outperformed its overall industry.
Next quarter’s earnings estimate for PRTA is -$1.22 with a range of -$2.07 to -$0.50. The previous quarter’s EPS was -$1.12. PRTA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.18% of the time in the same period. In the last calendar year PRTA has Outperformed its overall industry.

PRTA Sales Forecast

Next quarter’s sales forecast for PRTA is $6.95M with a range of $0.00 to $37.50M. The previous quarter’s sales results were $2.83M. PRTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year PRTA has Outperformed its overall industry.
Next quarter’s sales forecast for PRTA is $6.95M with a range of $0.00 to $37.50M. The previous quarter’s sales results were $2.83M. PRTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year PRTA has Outperformed its overall industry.

PRTA Stock Forecast FAQ

What is PRTA’s average 12-month price target, according to analysts?
Based on analyst ratings, Prothena’s 12-month average price target is 24.29.
    What is PRTA’s upside potential, based on the analysts’ average price target?
    Prothena has 299.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRTA a Buy, Sell or Hold?
          Prothena has a consensus rating of Moderate Buy which is based on 4 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Prothena’s price target?
            The average price target for Prothena is 24.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $81.00 ,the lowest forecast is $4.00. The average price target represents 299.51% Increase from the current price of $6.08.
              What do analysts say about Prothena?
              Prothena’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of PRTA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis